Abstract
BackgroundBasal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (CSCC) share exposure to UV light as the dominant risk factor, and these tumors therefore harbor high mutation burdens. In other...
Highlights
Basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (CSCC) share exposure to Ultraviolet light (UV) light as the dominant risk factor, and these tumors harbor high mutation burdens
High mutation burden has been associated with clinical benefit from therapy with antibodies directed against the Programmed Death 1 (PD-1) immune checkpoint receptor [4]
We report the first confirmed partial response in a patient with metastatic BCC treated with a PD-1 inhibitor (REGN2810), as well as an ongoing complete response in a patient with metastatic CSCC
Summary
We describe a radiographic complete response in a CSCC patient and the first reported confirmed partial response in a BCC patient treated with the anti-PD-1 monoclonal antibody REGN2810. A general principle appears to be that UV-associated skin cancers beyond melanoma are sensitive to PD-1 blockade. A reductionist model would predict that UV-associated tumors with higher load of non-synonymous mutations will be more responsive to PD-1 blockade than those with lower mutation load. The accessibility of UV-associated skin tumors for biopsy should allow clinical studies of patients with these cancers to illuminate these core concepts in immuno-oncology. An ongoing phase 2 trial will estimate the overall response rate of REGN2810 in patients with unresectable or metastatic CSCC (NCT02760498), and a similar study of REGN2810 in BCC is planned for patients who have been previously treated with hedgehog pathway inhibitors. Abbreviations C4-C6: 4th through 6th cervical vertebrae; Gy: Gray; kg: Kilogram; mg: Milligram; NGS: generation DNA sequencing; PD-L1: Programmed death-ligand 1; UV: Ultraviolet light
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
